Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules
Clinical Application Research on Differentiating Benign and Malignant Pulmonary Nodules Based on Multi-omics Detection Technology
Zhao Jun
150 participants
Jun 1, 2025
OBSERVATIONAL
Conditions
Summary
Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer
Eligibility
Inclusion Criteria5
- Patient underwent a ct examination
- Patient was confirmed to have pulmonary nodules
- Patient has been determined to undergo surgical treatment
- There are clear pathological results
- The clinicopathological data are complete
Exclusion Criteria10
- Patient has no ct examination results
- Refuse surgical treatment
- Patient has no clear pathological diagnosis
- Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.
- Patients with tumor emergencies that require immediate treatment.
- Poor vascular conditions.
- Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.
- Patients with hematogenic infectious diseases, such as HBV.
- Patients with psychiatric disorders or severe mental illnesses.
- Patients who have difficulty communicating or are unable to be followed up for a long time
Interventions
Research on the in vitro Stimulation of Pbmc by Tumor Antigen Nanoparticles PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer-related T cells or cytokines in vitro. The content of this type of T cells or cytokines is positively correlated with tumors. On the contrary, the content of T cells or cytokines in patients with benign pulmonary nodules is negatively correlated with the tumor. Furthermore, the benign and malignant nature of pulmonary nodules in patients is determined through the combination of patient imaging data and clinicopathological data.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07047573